


# Spectrum Advantage Program

For patients who receive a positive result from the Empower hereditary cancer test...



Natera is committed to helping prospective parents in their fertility journey. Natera offers Spectrum preimplantation genetic testing (PGT-M and PGT-A) at a discounted rate of \$995 for patients who test positive with Empower and choose to pursue in vitro fertilization (IVF). Empower determines if you have increased risk for common hereditary cancers.

## Who is eligible for the Spectrum Advantage Program?



## Empower hereditary cancer testing



Empower is a genetic test for those who want to know more about their risk of developing cancer, why it might be common in their family, or want to inform treatment options following a cancer diagnosis.

A positive result means that you could be at increased risk for developing common hereditary cancers such as breast, ovarian, colorectal, prostate, or pancreatic cancers. Natera's genetic counselors can help you understand what your positive result means for your cancer risk and for your future children.

Text **EMPOWER** to **484848** to watch a short informational video about Empower.

Text **SESSION** to **484848** to schedule a complimentary 15-minute call with a board-certified genetic counselor before or after your test.

## Spectrum PGT-M + PGT-A



PGT-M<sup>1</sup> screens a small sample of cells removed from an embryo to help identify whether an embryo is affected by a genetic condition. For individuals who know they are carriers of a genetic condition caused by a single gene, PGT-M reduces the chance of having a child affected by a condition.

PGT-M improves the chance of a healthy pregnancy when performed concurrently with PGT-A,<sup>2</sup> which tests the embryo sample for the correct number of chromosomes.<sup>3</sup>

Text **PGT** to **484848** to learn more about Spectrum.

### References:

- 1 Preimplantation Genetic Testing for Monogenic / Single Gene Conditions
- 2 Preimplantation Genetic Testing for Aneuploidy
- 3 Simon et al. *Fertil Steril*. 2018; 110(1):113–121.

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | [natera.com](http://natera.com)

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2021 Natera, Inc. All Rights Reserved. NAT\_EMP\_OS\_EmpowerSpectrumAdvantageProgram\_20210809\_NAT-8020526

